Ligand really is turning into an impressive story. Over the last 2 years, nothing has gone wrong for them. Everything is getting approved, all the data is looking good. The shots on goal approach has fallen out of favor with big pharma because they were going broke trying to pay for everything but Ligand really has it figured out. It works beautifully when someone else pays all development costs!
They've done well but frankly, the development of this drug had nothing to do with Ligand. Wyeth had a program with Ligand but the collaborative part of the program had very little to do with estrogens. If you look at all the patents and so on, no Ligand folks listed anywhere. Ligand didn't even know the bazedoxifene structure until it was already in development. Wyeth paid royalties for a screen that had nothing to do with this compound, it was more or less a contractual obligation. Nevertheless, they will benefit so more power to them. DuaVee is really a big advance in hrt for women, the progestins in normal HRT are the source of 90% of the troubles, by replacing it with bazedoxifene, they came up with a much better therapy. Hopefully Pfizer will put a little marketing muscle behind it as it offers considerable safety and tolerability improvements over progestin containing regimens, just a matter of being able to get the word out. Unfortunately, its just about impossible to say what the true advantages of a drug are without risking legal or regulatory liability. Good luck!